The anovulatory patient. An orderly approach to evaluation and treatment.
Ovulatory dysfunction is a leading cause of female infertility in the United States. Fortunately, ovulatory dysfunction is often amenable to treatment. Thorough testing is necessary to identify the exact cause of anovulation before conventional ovulation-inducing therapy is started. Careful patient monitoring is essential to avoid risks such as the ovarian hyperstimulation syndrome. Several newer ovulation-inducing agents are available for use in special situations.
D000858:Anovulation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000209:etiology*; D016729:Leuprolide; D008596:Menotropins / Q000627:therapeutic use; D010062:Ovulation Induction; D010906:Pituitary Hormone-Releasing Hormones / Q000627:therapeutic use
D010906:Pituitary Hormone-Releasing Hormones; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D008596:Menotropins; D005640:Follicle Stimulating Hormone; D016729:Leuprolide